Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 10/2010; 107(42):18143-8. DOI: 10.1073/pnas.1003919107
Source: PubMed

ABSTRACT Effective treatment of brain neurological disorders such as Alzheimer's disease, multiple sclerosis, or tumors should be possible with drug delivery through blood-brain barrier (BBB) or blood-brain tumor barrier (BTB) and targeting specific types of brain cells with drug release into the cell cytoplasm. A polymeric nanobioconjugate drug based on biodegradable, nontoxic, and nonimmunogenic polymalic acid as a universal delivery nanoplatform was used for design and synthesis of nanomedicine drug for i.v. treatment of brain tumors. The polymeric drug passes through the BTB and tumor cell membrane using tandem monoclonal antibodies targeting the BTB and tumor cells. The next step for polymeric drug action was inhibition of tumor angiogenesis by specifically blocking the synthesis of a tumor neovascular trimer protein, laminin-411, by attached antisense oligonucleotides (AONs). The AONs were released into the target cell cytoplasm via pH-activated trileucine, an endosomal escape moiety. Drug delivery to the brain tumor and the release mechanism were both studied for this nanobiopolymer. Introduction of a trileucine endosome escape unit resulted in significantly increased AON delivery to tumor cells, inhibition of laminin-411 synthesis in vitro and in vivo, specific accumulation in brain tumors, and suppression of intracranial glioma growth compared with pH-independent leucine ester. The availability of a systemically active polymeric drug delivery system that passes through the BTB, targets tumor cells, and inhibits glioma growth gives hope for a successful strategy of glioma treatment. This delivery system with drug release into the brain-specific cell type could be useful for treatment of various brain pathologies.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: β-poly(malic acid) (PMLA) can be used as a pro-drug or for a drug-delivery system. Effects of pH, dissolved oxygen concentration (DO) and stirring speed were investigated to improve PMLA production by A. pullulans ipe-1. RESULTS: The strain produced a high PMLA concentration when pH and DO remained at about 6.0 and above 70%, respectively, and the yeast-like cells were the main PMLA producers. To further promote PMLA production, the cultivation could be divided into three phases. In phase I, cell growth was accelerated by maintaining high DO (>70%) with a constant stirring speed of 800 rpm. In phase II, PMLA production was increased by controlling DO at 70% using the automatically controlled stirring speed. In phase III, PMLA production on per gram of glucose (Yp/s) was enhanced by keeping DO at 70%, and using a low stirring speed to decrease cell growth. Compared with batch cultures, a higher PMLA yield was obtained with this strategy, i.e. PMLA production and Yp/s increased by 15% and 18%, respectively. CONCLUSION: Control strategies for pH, DO and stirring speed provide a good reference for process development and optimization of PMLA production. © 2012 Society of Chemical Industry
    Journal of Chemical Technology & Biotechnology 05/2013; 88(5). · 2.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In Alzheimer's disease, progressive supranuclear palsy, and a number of other neurodegenerative diseases, the microtubule associated protein tau aggregates to form intracellular neurofibrillary tangles and glial tangles, abnormal structures that are part of disease pathogenesis. Disorders with aggregated tau are called tauopathies. Presently, there are no disease-modifying treatments for this disease class. Tau is encoded by the MAPT gene. We propose that reducing MAPT expression and thus the amount of tau protein made could prevent aggregation, and potentially be an approach to treat tauopathies. We tested 31 morpholinos, complementary to the sense strand of the MAPT gene to identify oligonucleotides that can downregulate MAPT expression and reduce the amount of tau protein produced. Oligonucleotides were tested in human neuroblastoma cell lines SH-SY5Y and IMR32. We identified several morpholinos that reduced MAPT mRNA expression up to 50% and tau protein levels up to ~80%. The two most potent oligonucleotides spanned the 3' boundary of exons 1 and 5, masking the 5'-splice sites of these exons. Both morpholinos induced skipping of the targeted exons. These in vitro findings were confirmed in mice transgenic for the entire human MAPT gene and that express human tau protein. These studies demonstrate the feasibility of using modified oligonucleotides to alter tau expression.
    Molecular therapy. Nucleic acids. 07/2014; 3:e180.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose A biodegradable PEG-PLGA nanoparticle (NP) modified by transferrin (Tf) was conceived. Doxorubicin (Dox), a widely used antitumor agent, without passing through the BBB, which limited its utility on glioma, was encapsulated inside (Tf-NP-Dox). Furthermore, its therapeutic efficacy to glioma was evaluated both in vitro and in vivo. Methods Tf-NP-Dox was prepared via modified single emulsion method. Its characterization including size, Drug loading capacity (DLC), entrapment efficiency (EE), Tf number on Tf-NP-Dox surface were estimated. The antitumor efficiency in vitro was evaluated via MTT assay. The transmembrane transportation was evaluated via HPLC assay. The antitumor efficiency in vivo was assessed on C6 glioma intracranial implant rats model. Results The average diameter of Tf-NP-Dox is around 200 nm with surface Tf molecule number per Tf-NP-Dox approximately 25. MTT assay demonstrated stronger cytotoxicity of Tf-NP-Dox to C6 glioma cells (P<0.01). HPLC assay showed Tf-NP-Dox transport Dox into C6 with higher efficiency compare to NP-Dox or Dox (P<0.01). On C6 glioma bearing rat, Tf-NP-Dox could transport more Dox into tumors tested by HPLC assay (P<0.05), and extended life span markedly compared to NP-Dox or Dox (P<0.05). Conclusions Tf-NP-Dox had a potential of glioma targeting and had a better therapeutic effect to glioma both in vitro and in vivo.
    Advanced Materials Research. 08/2013; 750-752:1643-1650.

Full-text (2 Sources)

Available from
May 22, 2014